• Tamsulosin: Optimizing Urological Disease Research Workflows

  2026-05-10

  Tamsulosin's selectivity for α₁A-adrenergic receptors makes it a gold-standard research tool for studying smooth muscle relaxation and postoperative urinary retention prevention. This article delivers actionable experimental workflows, protocol parameters, and troubleshooting approaches based on the latest meta-analytical evidence and high-purity sourcing from APExBIO.

• SB 203580: Selective p38 MAPK Inhibitor for Signal Pathway R

  2026-05-09

  SB203580 (4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine) is a potent, ATP-competitive inhibitor of the p38 MAPK signaling pathway. This compound enables precise dissection of kinase-mediated cellular processes and is a benchmark reagent for inflammation, neuroprotection, and multidrug resistance studies.

• PFOS Triggers Ferroptosis and ER Stress in HK-2 Cells: Mecha

  2026-05-09

  This article analyzes a recent study revealing how perfluorooctane sulfonate (PFOS) induces injury in human kidney (HK-2) cells via ferroptosis and endoplasmic reticulum (ER) stress pathways. The findings provide mechanistic clarity for nephrotoxicity research and inform the design of ER stress modulation experiments.

• iPSC-Based Clinical Trial Selection for Ultrarare Disease Mu

  2026-05-08

  Sequiera et al. present a patient-specific induced pluripotent stem cell (iPSC) platform enabling preclinical drug efficacy and safety screening for individuals with ultrarare mutations. This approach addresses the limitations of traditional trial-and-error clinical trial inclusion for patients with novel pathogenic variants, offering a data-driven path to personalized medicine.

• Transmission Dynamics of Carbapenemase Genes in CREC: Insigh

  2026-05-07

  This study provides a detailed molecular and epidemiological assessment of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) collected from eight teaching hospitals in Guangdong during the COVID-19 pandemic. The research highlights high CEG prevalence, multidrug resistance, and efficient gene transmission, informing future antibacterial research and infection control strategies.

• PFOS Induces Ferroptosis and ER Stress in HK-2 Renal Cells

  2026-05-07

  This study provides direct evidence that perfluorooctane sulfonate (PFOS) triggers injury in human kidney HK-2 cells by activating both ferroptosis and endoplasmic reticulum (ER) stress pathways. These mechanistic insights clarify how environmental PFOS exposure can contribute to renal cell damage, establishing a foundation for future studies targeting ER stress modulation.

• Carfilzomib (PR-171): Unraveling Proteasome Inhibition and M

  2026-05-06

  Explore the advanced mechanisms of Carfilzomib (PR-171) in cancer research, focusing on its role in proteasome inhibition and the induction of apoptosis, paraptosis, and ferroptosis. This article provides new insights for experimental design, grounded in recent translational oncology breakthroughs.

• TAK-715: Mechanistic Insights and Precision Protocols for p3

  2026-05-06

  Explore the unique molecular mechanism of TAK-715, a potent p38 MAPK inhibitor, and discover advanced protocol guidance and novel assay strategies grounded in the latest structural science. This article delivers unparalleled depth for researchers studying inflammation and cytokine signaling modulation.

• Hepatic sEH Drives Osteoclastogenesis via Nrf2 Suppression i

  2026-05-05

  This study uncovers a liver-bone axis wherein hepatic soluble epoxide hydrolase (sEH) promotes osteoclast differentiation by suppressing the Nrf2 signaling pathway, leading to redox imbalance and osteoporosis. The findings introduce new mechanistic insight into bone metabolism and establish sEH as a potential target for modulating osteoclastogenesis in translational research.

• Nystatin (Fungicidin): Mechanism-Driven Frontiers in Antifun

  2026-05-05

  This thought-leadership article delivers a mechanism-centric roadmap for translational researchers leveraging Nystatin (Fungicidin) in antifungal discovery. Integrating recent synergistic evidence with strategic guidance, it decodes how ergosterol targeting and adhesion inhibition can be exploited to surmount resistance, optimize animal models, and advance clinical relevance—positioning APExBIO’s Nystatin as an essential tool for future-proof antifungal research.

• Tiamulin (Thiamutilin): Protocols and Innovation for Veterin

  2026-05-04

  Tiamulin (Thiamutilin) is revolutionizing veterinary infectious disease and inflammation research with its unique dual action as a pleuromutilin antibiotic and signaling pathway modulator. This guide translates the latest metabolic, mechanistic, and workflow evidence into actionable, troubleshooting-oriented protocols for both in vitro and in vivo applications.

• PSA-CD56/Siglec-7 Axis Drives Immune Evasion in ccRCC

  2026-05-04

  This study identifies polysialylated CD56 (PSA-CD56) as a novel glyco-immune checkpoint promoting immune evasion in clear cell renal cell carcinoma (ccRCC) through engagement with Siglec-7 on CD8 T cells. By elucidating the molecular mechanism and demonstrating that blocking this axis restores T cell activity and induces tumor cell apoptosis, the research offers a promising direction for overcoming immunotherapy resistance.

• Dacarbazine (SKU A2197): Reliable DNA Alkylation for Oncolog

  2026-05-03

  This article guides biomedical researchers and lab technicians through real-world challenges in cytotoxicity and viability assays, showing how Dacarbazine (SKU A2197) delivers reproducible, data-driven solutions. Readers gain scenario-based insights on experimental design, protocol optimization, and vendor selection, with actionable references to APExBIO's validated product.

• Curcumin Inhibits PBDE-47-Induced NETs by Targeting Nrf2-ROS

  2026-05-02

  This study reveals that PBDE-47, a common environmental pollutant, strongly induces neutrophil extracellular trap (NET) formation via ROS production. Importantly, curcumin counteracts this effect by modulating Nrf2-dependent antioxidant pathways, offering mechanistic insight into immune toxicity and potential intervention strategies.

• Ertugliflozin (PF-04971729): Precision Tools for Cardiometab

  2026-05-02

  Explore Ertugliflozin (PF-04971729) as a research catalyst for advanced diabetes, cardiovascular, and mucosal studies. This in-depth guide deciphers unique mechanistic and translational assay considerations, differentiating APExBIO’s solution from standard SGLT2 inhibitor content.

456 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page